Microbix Biosystems launches new products to support H3N2 flu testing

Microbix Biosystems (MBXBF) announces the commercial launch of QAPs quality assessment products and availability of QUANTDx reference materials to support antigen or molecular tests for H3N2 strains of seasonal Influenza A. Cameron Groome, CEO & President of Microbix, commented, “We believe it’s critical that Microbix creates QAPs for emerging infectious diseases in a timely manner. Effective public health responses to all outbreaks are predicated on accurate and reliable, tracking, screening, and diagnosis – needs that are imperiled when quality management tools to support testing aren’t readily available. It is Microbix’s privilege to be a Canadian-led company that is improving healthcare outcomes worldwide with Ontario Made products.”